# AUTHOR INDEX

(S = supplement; P = proceedings)


ABERNETHY, D. R., GREENBLATT, D. J., LOCKNISKAR, A., OCHS, H. R., HARMATZ, J. S. & SHADER, R. I. Obesity effects on nitrazepam disposition, 551

ABERNETHY, D. R. *see* NELSON, E. B.

ABILA, B., WILSON, J. F., MARSHALL, R. W. & RICHENS, A. Exercise induced hand tremor: a possible test for $\beta_2$-adrenoceptor selectivity in man?, 104

ABISCH, E. *see* GREVEL, J.

ABRAMS, S. M. L., HARRY, T. V. A., HEDGES, A., MURRAY, G. R. & TURNER, P. Pharmacodynamic and pharmacokinetic comparison of two formulations of lorazepam with placebo, 229P

ADAM, K. & OSWALD, I. The hypnotic effects of an antihistamine, 715

ADAM, K. & OSWALD, I. No effects on sleep of a histamine $H_1$-receptor antagonist: temelastine, 718

ADAM, K. *see* OSWALD, I.

ADAMS, P. C., SLOAN, P., MORLEY, A. R. & HOLT, D. W. Peripheral neutrophil inclusions in amiodarone treated patients, 736

ADELHØJ, B. *see* PETRING, O. U.

AGADAH, W. O. *see* KIRBY, M. J.

AJAYI, A. A., ELLIOTT, H. L. & REID, J. L. The pharmacodynamics and dose–response relationships of the angiotensin converting enzyme inhibitor, cilazapril, in essential hypertension, 167

ALDHOUS, M. *see* FRANEY, C.

AL-KHAWAJA, CARUANA, M. P., LAHIRI, A., WHITTINGTON, J. R., LEWIS, J. G. & RAFTERY, E. B. Nicardipine and verapamil in essential hypertension, 273S

AL-KHAWAJA, I. M. *see* RODRIGUES, E. A.

ALLEN, J. G. *see* HARDIE, R. J.

ALT, U., LEIGH, P. J., WILKINS, A. J., MORRIS, P. K. & MACDERMOT, J. Desensitization of iloprost responsiveness in human platelets follows prolonged exposure to iloprost *in vitro*, 118

ALTHOFF, P. H. *see* DEMISCH, K.

ALVEYN, C. *see* HIBBERD, S. G.

ALWAZIR, Y. A. *see* WILLIAMS, P. E.

AMEER, B. *see* NELSON, E. B.

ANDERSEN, R. B. *see* LUND, B.

ANDERSON, I. M. & COWEN, P. J. Clomipramine enhances the prolactin response to L-tryptophan, 216P

ARENDT, J. *see* FRANEY, C.

ARKINSTALL, S. Y. *see* NUTT, D. J.

ARMSTRONG, C., GARNHAM, J. & BLACKWOOD, R. Comparison of the efficacy of nicardipine and nifedipine in patients with chronic stable angina, 325S

ARMSTRONG, C., GARNHAM, J., BLACKWOOD, R., LAHER, M. & COUNIHAN, T. Long-term safety and efficacy of nicardipine in the treatment of stable angina pectoris, 331S

ARONSON, J. K. *see* BOON, N. A.

ARONSON, J. K. *see* RAPEPORT, W. G.

ATEIA, J. *see* OWENS, D. R.

AUTY, R. M. *see* NEALE, M. G.

BACK, D. J. *see* GRIMMER, S. F. M.

BACK, D. J. *see* ROGERS, S. M.

BACKHOUSE, G. *see* BENTLEY, D. P.

BAKHLE, Y. S. & YEATS, D. A. Liberation of arachidonate from phospholipids by extracts of human lung, 213P

BANIM, S. O. *see* MALTZ, M. B.

BARR, R. M. *see* WONG, E.

BARRADAS, M. A. *see* JEREMY, J. Y.

BASILISCO, G., CAMBONI, G., BOZZANI, A. & BIANCHI, P. A. Loperamide and oro–caecal transit delay, 371

BAYER, A. J. *see* WATT, A. H.

BEASTALL, G. H. *see* SEMPLE, C. G.

BECKER, R. H. A., STRUTHERS, A. D. & BROWN, M. J. Effect of captopril on changes in plasma noradrenaline induced by sodium nitroprusside, 409

BEGG, E. J. *see* WOOLNER, D. F.

BELLAMY, N., BUCHANAN, W. W. & GRACE, E. Double-blind randomized controlled trial of isoxicam *vs* piroxicam in elderly patients with osteoarthritis of the hip and knee, 149S

BENCINI, C. *see* PACIFICI, G. M.

BENTLEY, D. P., BACKHOUSE, G., HUTCHINGS, A., HADDON, R. L., SPRAAG, B. & ROUTLEDGE, P. A. Investigation of patients with abnormal response to warfarin, 37

BÈZES, H. *see* MASSART, P.

BIANCHI, P. A. *see* BASILISCO, G.

BIRKETT, D. J. *see* LELO, A.

BIRKETT, D. J. *see* MINERS, J. O.

BITTINER, S. B. & SMITH, S. E. β-adrenoceptor antagonists increase sinus arrhythmia, a vagotonic effect, 691

BJERLE, P., OLOFSSON, B. O. & GLIMVIK, O. Nicardipine and propranolol in angina pectoris: a comparative study with special reference to ergometer working capacity tests, 339S

BJÖRKMAN, A. *see* FU, S.

BLACK, J. Basic drug research in universities and industry, 5S

BLACKWOOD, R. *see* ARMSTRONG, C.

BLAKE, D. *see* GEORGE, C. F.

BLANC, M. *see* DOUSTE-BLAZY, PH.

BOCHNER, F. *see* GODFREY, P. P.

BOCHNIK, H. J. *see* DEMISCH, K.

BOETHIUS, G. *see* SJÖQVIST, F.

BOOBIS, A. R. *see* SPEIRS, C. J.

BOON, N. A., PUGH, S. E., HALLIS, K. F., ARONSON, J. K. & GRAHAME-SMITH, D. G. *In vivo* cation transport during short-term and long-term digoxin therapy, 27

BOOTH, K. *see* NICHOLLS, D. P.

BOUTAGY, J. *see* SUHARDJONO, D.

BOZZANI, A. *see* BASILISCO, G.

BRADLEY, C. M. & NICHOLSON, A. N. Opioid analgesics and performance: effects of codeine in man, 226P

BRADLEY, C. M. & NICHOLSON, A. N. Effects of μ-opioid receptor agonist (codeine phosphate) on visuo-motor coordination and dynamic visual acuity in man, 507

BRECKENRIDGE, A. M. The pharmaceutical industry and developing countries, 27S

BRECKENRIDGE, A. M. Closing remarks, 189S

BRECKENRIDGE, A. M. *see* CHOONARA, I. A.

BRECKENRIDGE, A. M. *see* COLEMAN, J. M.

BRECKENRIDGE, A. M. *see* HAYNES, B. P.

BRECKENRIDGE, A. M. *see* ROBERTS, D. H.

BREDESEN, J. E. & KIERULF, P. Relationship between $\alpha_1$-acid glycoprotein and distribution of disopyramide and mono-*N*-dealkyldisopyramide in whole blood, 281

BRINN, R., BRØSEN, K., GRAM, L. F., HAGHFELT, T. & OTTON, S. V. Sparteine oxidation is practically abolished in quinidine-treated patients, 194

BRODIE, M. J. *see* MCINNES, G. T.

BROOKS, P. Introductory remarks, 109S

BROOKS, P. Closing remarks, 189S

BROOKS, P. M. *see* GARRETT, R.

BRØSEN, K. Sparteine oxidation polymorphism in Greenlanders living in Denmark, 415

BRØSEN, K. *see* BRINN, R.

BROWN, D. *see* REILLY, A.

BROWN, K. *see* NEALE, M. G.

BROWN, M. J. *see* BECKER, R. H. A.

BROWN, S. T., FREEDMAN, D., DE VAULT, G. & SLAY, L. Safety, efficacy and pharmacokinetics of nicardipine in elderly hypertensive patients, 289S

BROWNWELL, J. *see* GREVEL, J.

BRUCE, M., SCOTT, N., LADER, M. & MARKS, V. The psychopharmacological and electrophysiological effects of single doses of caffeine in healthy human subjects, 81

BRUCE, M. *see* LADER, M.

BUCHANAN, K. D. *see* SEMPLE, C. G.

BUCHANAN, N. *see* LAFERLA, G.

BUCHANAN, W. W. *see* BELLAMY, N.

BÜHRING, K. U. *see* LEOPOLD, G.

BULSTRODE, S. J. *see* COLLINS, A. J.

BUNCH, C. *see* LOOAREESUWAN, S.

BURSTEIN, E. S. *see* FRIEDMAN, H.

BURTON, S. *see* FRANEY, C.

BUTZ, R. F. *see* FINDLAY, J. W. A.

CALDWELL, J., STAIB, A. H., COTGREAVE, I. A. & SIEBERT-WEIGEL, M. Theophylline pharmacokinetics after intravenous infusion with ethylenediamine or sodium glycinate, 351

CALDWELL, J., STROLIN-BENEDETTI, M. & WEIL, A. Comparative metabolism of fenofibrate in rats and human volunteers, 219P

CALLENDER, J. S. Psychological effects of nicardipine and propranolol on hypertensive patients, 267S

CAMBONI, G. *see* BASILISCO, G.

CAMELLINI, L. *see* CHIODERA, P.

CAMERON, C. M. *see* CAMERON, H. A.

CAMERON, H. A., CAMERON, C. M. & RAMSAY, L. E. Comparison of single doses of ketanserin and placebo in chronic stable angina, 114

CAMM, A. J. *see* MALTZ, M. B.

CAMPBELL, D. B., DREW, M. & CHIGNON, J. C. Prediction of prolonged *in vivo* β-adrenoceptor blockade by tertatolol from plasma concentrations and *in vitro* receptor binding studies, 205P

CAMPBELL, I. A. *see* WILLIAMS, P. E.

CANADA, A. T. *see* JOHNSON, B. F.

CARDOE, N. & DUDLEY HART, F. Double-blind multicentre UK hospital studies of isoxicam *vs* naproxen, 167S

CARUANA, M. P. *see* AL-KHAWAJA, I. M.

CASIGLIA, E., GAVA, R., SEMPLICINI, A., NICOLIN, P. & PESSINA, A. C. The mechanism of the hypertensive effects of ketanserin: a comparison with metoprolol, 751

CASSIDY, S. L. & PEARSON, R. M. Effects of trazodone and nadolol upon human sperm motility, 119

CELLE, G. *see* VARINO, V.

CELOTTI, F. *see* DE PAOLIS, C.

CHAKRABORTY, J. *see* SCOTT, N. R.

CHALLENOR, V. F., WALLER, D. G., GRUCHY, B. S., RENWICK, A. G., GEORGE, C. F., MCMURDO, E. T. & MCEWEN, J. The effects of food and posture on the pharmacokinetics of a biphasic release preparation of nifedipine, 565

CHALLENOR, V. F. *see* WALLER, D. G.

CHANTHAVANICH, P. *see* LOOAREESUWAN, S.

CHASSEAUD, L. F. *see* FAULKNER, J. K.

CHECKLEY, S. *see* FRANEY, C.

CHESTNUTT, W. N. *see* DUNDEE, J. W.

CHESTNUTT, W. N. *see* LYNAS, A. G. A.

CHEUNG, R. *see* DICKINS, J.

CHIBA, K. *see* KUBOTA, K.

CHIGNON, J. C. *see* CAMPBELL, D. B.

CHIODERA, P., VOLPI, R., DELSIGNORE, R., MARCHESI, C., SALATI, G., CAMELLINI, L., ROSSI, G. & COIRO, V. Different effects of metoclopramide and domperidone on arginine–vasopressin secretion in man, 479

CHOLERTON, S. *see* CHOONARA, I. A.

CHOLERTON, S. *see* HAYNES, B. P.

CHOONARA, I. A., HAYNES, B. P., CHOLERTON, S., BRECKENRIDGE, A. M. & PARK, P. K. Enantiomers of warfarin and vitamin $K_1$ metabolism, 729

CHOONARA, I. A. *see* HAYNES, B. P.

CHORARIA, S. K., TAYLOR, D. & PILCHER, J. Haemodynamic effects of oral enoximone in severe congestive heart failure, 209P

CLUCAS, A. T. *see* LAFERLA, G.

COIRO, V. *see* CHIODERA, P.

COLEMAN, J. W., YEUNG, J. H. K., ROBERTS, D. H., BRECKENRIDGE, A. M. & PARK, B. K. Drug-specific antibodies in patients receiving captopril, 161

COLLIER, J. *see* SCOTT, A. K.

COLLINS, A. J., HUTTON, C. W. & BULSTRODE, S. J. The effects of anti-inflammatory drugs on the intradermal monosodium urate model of human acute inflammation, 243P

COLLINS, A. J. *see* NOTARIANNI, L. J.

COLLINS, W. *see* FEELY, J.

CONNACHER, A. A., EL DEBANI, A. H. & STEVENSON, I. H. A study of the influence of nifedipine on the disposition and hypoglycaemic action of glipizide, 240P

CONRADI, E. C. *see* WALLE, T.

CONTE, D. *see* DOUSTE-BLAZY, PH.
COOMBES, E. J. *see* HIBBERD, S. G.
COTGREAVE, I. A. *see* CALDWELL, J.
COTONAT, J. *see* DOUSTE-BLAZY, PH.
COUNIHAN, T. *see* ARMSTRONG, C.
COWEN, P. J. *see* ANDERSON, I. M.
COXHEAD, P. F. *see* MURRAY, T. S.
CREAMER, J. E. *see* MALTZ, M. B.
CREAN, G. P. *see* LAFERLA, G.
CRITCHLEY, J. A. J. H., NIMMO, G. R., GREGSON, C. A., WOOLHOUSE, N. M. & PRESCOTT, L. F. Inter-subject and ethnic differences in paracetamol metabolism, 649
CROMBIE, I. K. The role of record linkage in post-marketing drug surveillance, 77S
CROMIE, B. W. Drug research and development in the pharmaceutical industry, 5S
CROSS, G. *see* DICKINS, J.
CUISINAUD, G. *see* FERRY, N.
CULLEN, M. *see* FEELY, J.
CUNNINGHAM, F. M. *see* WONG, E.
CUSHLEY, M. J., WEE, L. H., HOLGATE, S. T. The effect of inhaled 5-hydroxytryptamine (5-HT, serotonin) on airway calibre in man, 487

DANDONA, P. *see* JEREMY, J. Y.
DARRAGH, A. S. *see* GEORGE, C. F.
DAVIDSON, A. V. M. *see* HOCKINGS, N.
DAVIDSON, D. L. W. *see* HOCKINGS, N.
DAVIES, D. S. *see* SPEIRS, C. J.
DAVIES, D. W. *see* MALTZ, E. B.
DAVIES, I. B., GUINEBAULT, P., JOHNSON, E. S., SEYMOUR, D., SINCLAIR, A. J. & WARRINGTON, S. J. α-Adrenoceptor antagonism by alfuzosin in man: effects of phenylephrine pressor dose-responses, 231P
DAVIES, I. B. *see* WHITCROFT, I.
DAVIES, S. L. *see* THEODOROU, A. E.
DE PAOLIS, C., FARINA, R., PIANEZZOLA, E., VALZELLI, G., CELOTTI, F. & PONTIROLI, A. E. Lack of pharmacokinetic interaction between cholestyramine and acipimox, a new lipid lowering drug, 496
DE SCHEPPER, P. J. *see* TJANDRA-MAGA, T. B.
DE VOCHT, M. *see* SYVALAHTI, E. K. G.
DEERING, A. H., RIDDELL, J. G., HARRON, D. W. G. & SHANKS, R. G. Effect of acute and chronic administration of indoramin on baroreceptor function in man, 231P
DELSIGNORE, R. *see* CHIODERA, P.
DEMISCH, K., BOCHNIK, H. J., NICKELSEN, T., ALTHOFF, P. H., SCHÖFFLING, K. & RIETH, R. Melatonin and cortisol increase after fluvoxamine, 620
DENHAM, M. J. *see* DICKINS, J.
DENHAM, M. J. *see* NICHOLSON, P. W.
DESHMUKH, A. A. *see* NICHOLSON, P. W.
DE VAULT, G. *see* BROWN, S. T.
DICKINS, J., CROSS, G., TERRY, V. G., NICHOLSON, P. W., SULLENS, C. M., CHEUNG, R., DENHAM, M. J. & DOBBS, S. M. Measurement of compliance with drug therapy in the elderly: a new approach, 246P
DICKSON, B. *see* RANDOLPH, W. C.
DI TIMOTEO, E. *see* VARINO, V.
DOBBS, S. M. *see* DICKINS, J.
DOBBS, S. M. *see* NICHOLSON, P. W.
DOLLERY, C. T. Problems related to drug development, 31S
DOMBEY, S. L. Is the current training of pharmaceutical staff adequate?, 61S
DONKER, J. M. *see* VAN DER MEULEN, J.
DONNELLY, R., ELLIOTT, H. L. & REID, J. L. Nicardipine combined with enalapril in patients with essential hypertension, 283S
DORROW, R. *see* DUKA, TH.
DOURY, P. & ROUX, H. Isoxicam *vs* ketoprofen in ankylosing spondylitis, 157S
DOUSTE-BLAZY, PH., BLANC, M., MONTASTRUC, J. L., CONTE, D., COTONAT, J. & GALINIER, F. Is there any interaction between digoxin and enalapril?, 752
DOW, R. J. & GRAHAM, D. J. M. A review of the human metabolism and pharmacokinetics of nicardipine hydrochloride, 195S
DOWNIE, C. Aspects of drug research and development, 3S
DREW, M. *see* CAMPBELL, D. B.
DUDLEY HART, F. *see* CARDOE, N.
DUKA, TH., HOLLER, L., OBENG-GYAN, R. & DORROW, R. Initial human pharmacology of the neutral benzodiazepine receptor antagonist β-carboline ZK 93 426, 228P
DUNDEE, J. W., CHESTNUTT, W. N., GHALY, R. G. & LYNAS, A. G. A. Reduction in emetic effects of opioid pre-anaesthetic medication by acupuncture, 214P
DUNDEE, J. W. *see* FEE, J. P. H.
DUNDEE, J. W. *see* LYNAS, A. G. A.
DUNNING, A. J. *see* VISSER, C. A.
DYLEWICZ, P. *see* KIRCH, W.

EAST, B. W. *see* MURRAY, T. S.
EAST, P. B. *see* PRINGLE, T. H.
EDSTEIN, M. D., VEENENDAAL, J. R., NEWMAN, K. & HYSLOP, R. Excretion of chloroquine, dapsone and pyrimethamine in human milk, 733
EDVINSSON, L., IKOMI-KUMM, J. & MONTI, M. Microcalorimetric studies on the effect of adenosine receptor agonists and xanthine derivatives on overall metabolism in human platelets, 685
EDWARDS, G. *see* LOOAREESUWAN, S.
EGSMOSE, C. *see* LUND, B.
EICHELBAUM, M., MINESHITA, S., OHNHAUS, E. E. & ZEKORN, C. The influence of enzyme induction on polymorphic sparteine oxidation, 49
EICHELBAUM, M. *see* KLOTZ, U.
EKMAN, L. *see* FADEKE ADEROUNMU
EL DEBANI, A. H. *see* CONNACHER, A. A.
ELLIOTT, H. L., JONES, C. R., MEREDITH, P. A. & REID, J. L. Adimolol: a β-adrenoceptor antagonist for once weekly administration?, 235P
ELLIOTT, H. L. *see* AJAYI, A. A.
ELLIOTT, H. L. *see* DONNELLY, R.
ELLIOTT, H. L. *see* MEREDITH, P. A.
ELLIS, A. *see* GRIMMER, S. F. M.
ELLIS, F. R. *see* SIMPSON, K. H.
EMMETT, M. *see* LEE, S. M.
ERICSSON, O. *see* FU, S.
ERICSSON, O. *see* OFORI-ADJEI, D.

FADEKE ADEROUNMU, A., SALAKO, L. A., LINDSTRÖM, B., WALKER, O. & EKMAN, L. Comparison of the pharmacokinetics of chloroquine after single intravenous and intramuscular administration in healthy Africans, 559
FARINA, R. *see* DE PAOLIS, C.
FARRELL, G. C. *see* WILLIAMS, S. J.
FAULKNER, J. K., MCGIBNEY, D., CHASSEAUD, L. F., PERRY, J. L. & TAYLOR, I. W. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily, 21
FAULKNER, J. K. *see* SCOTT, A. K.
FEE, J. P. H. & DUNDEE, J. W. Antipyrine elimination is not increased by a single induction dose of thiopentone, 224P
FEELY, M. *see* PRICE, D.
FEELY, M. P. *see* PRICE, D. E.
FEELY, J., CULLEN, M. & COLLINS, W. Metabolic and endocrine consequences of calcium channel blockade, 231S
FERRIE, J. E. *see* NOTARIANNI, L. J.
FERRY, N., CUISINAUD, G., OUZAN, D., TREPO, C. & SASSARD, J. Pharmacokinetics of isoxicam in hepatic disease, 143S
FINDLAY, J. W. A., FOWLE, A. S. E., BUTZ, R. F., JONES, E. C., WEATHERLEY, B. C., WELCH, R. M. & POSNER, J. Comparative disposition of codeine and pholcodine in man after single oral doses, 61
FOLGERING, H. TH. M. *see* LAMMERS, J. W. J.
FOSTER, J. *see* RICHARDSON, T.
FOWLE, A. S. E. *see* FINDLAY, J. W. A.
FRAIS, M. A., SILKE, B., VERMA, S. P., SHARMA, S., REYNOLDS, G., JACKSON, N. & TAYLOR, S. H. Multiple haemodynamic dose–response effects of amlodipine in coronary artery disease, 232P
FRAIS, M. A. *see* SILKE, B.
FRANCHI, M. *see* PACIFICI, G. M.
FRANCIS, D. A. *see* WALLER, D. G.
FRANCIS, R. J. *see* PRINGLE, T. H.
FRANEY, C., ALDHOUS, M., BURTON, S., CHECKLEY, S. & ARENDT, J. Acute treatment with desipramine stimulates melatonin and 6-sulphatoxy melatonin production in man, 73
FRANK, G. J. *see* GEORGE, C. F.
FRANK, W. O. *see* RANDOLPH, W. C.
FRANKLIN, M. *see* NUTT, D. J.
FREEDMAN, D. *see* BROWN, S. T.
FRENDIN, T. J. *see* WOOLNER, D. F.
FRIEDMAN, F. K. *see* PELKONEN, O.
FRIEDMAN, H., GREENBLATT, D. J., BURSTEIN, E. S., HARMATZ, J. S. & SHADER, R. I. Population study of triazolam pharmacokinetics, 639
FROLDI, M. *see* MIADONNA, A.
FU, S., BJÖRKMAN, A., WÄHLIN, B., OFORDI-ADJEI, D., ERICSSON, O. & SJÖQVIST, F. *In vitro* activity of chloroquine, the two enantiomers of chloroquine, desethyl-chloroquine and pyronardine against *Plasmodium falciparum*, 93

GACHALYI, B. *see* PELKONEN, O.
GAILLARD, R. C. *see* GREVEL, J.
GALINIER, F. *see* DOUSTE-BLAZY, PH.
GARNHAM, J. *see* ARMSTRONG, C.
GARRETT, R., MANTHEY, B., VERNON-ROBERTS, B. & BROOKS, P. M. The effect of isoxicam–aspirin combinations on the polyurethane sponge implantation model in the rat, 125S
GAVA, R. *see* CASIGLIA, E.
GELBOIN, H. V. *see* PELKONEN, O.
GEORGE, C. F. Editorial note, 107S
GEORGE, C. F. Editor's note, 249
GEORGE, C. F., RENWICK, A. G., DARRAGH, A. S., HOSIE, J., BLAKE, D., VAN MARLE, W. & FRANK, G. J. A comparison of isoxicam pharmacokinetics in young and elderly subjects, 129S
GEORGE, C. F. *see* CHALLENOR, V.
GHALY, R. G. *see* DUNDEE, J. W.
GHALY, R. G. *see* LYNAS, A. G. A.
GILMORE, I. T. *see* GRIMMER, S. F. M.
GLEADHILL, D. N. S. *see* NICHOLLS, D. P.
GLIMVIK, O. *see* BJERLE, P.
GODFREY, P. P., BOCHNER, F. & GRAHAME-SMITH, D. G. Dose-dependent inhibition of phosphoinositide metabolism in human platelets by aspirin *in vitro* and *in vivo*, 443
GOLDBERG, A. Development of drug regulating authorities, 67S
GOLDIE, R. G., SPINA, D., HENRY, P. J., LULICH, K. M. & PATERSON, J. W. *In vitro* responsiveness of human asthmatic bronchus to carbachol, histamine, β-adrenoceptor agonists and theophylline, 669
GRACE, E. *see* BELLAMY, N.
GRAHAM, J. M. *see* DOW, R. J.
GRAHAME-SMITH, D. G. *see* BOON, N. A.
GRAHAME-SMITH, D. G. *see* GODFREY, P. P.
GRAHAME-SMITH, D. G. *see* RAPEPORT, W. G.
GRAM, L. F. *see* BRINN, R.
GREAVES, M. W. *see* WONG, E.
GREEN, J. H. *see* SIMPSON, K. H.
GREENBLATT, D. J. *see* ABERNETHY, D. R.
GREENBLATT, D. J. *see* FRIEDMAN, H.
GREENBLATT, D. J. *see* NELSON, E. B.
GREGSON, C. A. *see* CRITCHLEY, J. A. J. H.
GREVEL, J., BROWNELL, J., STEIMER, J. L., GAILLARD, R. C. & ROSENTHALER, J. Description of the time course of the prolactin suppressant effect of the dopamine agonist CQP 201-403 by an integrated pharmacokinetic–pharmacodynamic model, 1
GREVEL, J., KUTZ, K., ABISCH, E. & NUEESCH, E. Evidence for zero order absorption of cyclosporin A, 220P
GRGURINOVICH, N. *see* MINERS, J. O.
GRIFFIN, J. P. Survey of the spontaneous adverse drug reaction reporting schemes in fifteen countries, 83S
GRIMMER, S. F. M., BACK, D. J., ORME, M. L.'E., TJIA, J., GILMORE, I. T. & ELLIS, A. *In vitro* conjugation of ethinyloestradiol by coeliac mucosa and its bioavailability in coeliac patients, 217P
GRUCHY, B. S. *see* CHALLENOR, V.
GUENTERT, T. W. *see* RONCARNI, G.
GUINEBAULT, P. *see* DAVIES, I. B.
GUNDERT-REMY, U., KRÜDEWAGEN, B. & HILDEBRANDT, R. Plasma concentrations of theophylline and its metabolites in a theophylline intoxicated child—reevaluation of published $K_m$-values, 617

GUPPY, W. *see* LOGAN, R. L.

HADDON, R. L. *see* BENTLEY, D. P.
HAFIZULLAH, M. *see* SILKE, B.
HAGHFELT, T. *see* BRINN, R.
HALE, A. S. *see* THEODOROU, A. E.
HALLIS, K. F. *see* BOON, N. A.
HAMDY, N. A. T., KENNEDY, H. J., NICHOLL, J. & TRIGER, D. R. Sedation for gastroscopy: a comparative study of midazolam and Diazemuls in patients with and without cirrhosis, 643
HAMILTON-FARRELL, M. R. & NIGHTINGALE, J. J. Cardiac dysrhythmias, carbon dioxide tensions and blood halothane concentrations during dental anaesthesia, 212P
HAMILTON, C. A. & REID, J. L. Platelet α-adrenoceptors—a valid model for brain or vascular adrenoceptors?, 623
HANET, C., ROUSSEAU, M. F., VINCENT, M.-F. & POULEUR, H. Effects of nicardipine on myocardial metabolism and coronary haemodynamics: a review, 215S
HARDIE, R. J., MALCOLM, S. L., LEES, A. J., STERN, G. M. & ALLEN, J. G. The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on–off fluctuations, 429
HARMATZ, J. S. *see* ABERNETHY, D. R.
HARMATZ, J. S. *see* FRIEDMAN, H.
HARPER, C. *see* RAPEPORT, W. G.
HARRON, D. W. G. *see* DEERING, A. H.
HARRY, T. V. A. *see* ABRAMS, S. M. L.
HASAN, S. *see* HUGHES, A.
HAWKSBY, C. *see* HOWES, L. G.
HAY, A. *see* PRICE, D.
HAY, A. *see* PRICE, D. E.
HAYES, T. M. *see* OWENS, D. R.
HAYNES, B. P., CHOONARA, I. A., CHOLERTON, S., BRECKENRIDGE, A. M. & PARK, B. K. Enantiomers of warfarin and vitamin $K_1$ metabolism, 242P
HAYNES, B. P. *see* CHOONARA, I. A.
HEARNS, J. *see* LAFERLA, G.
HEDGES, A. *see* ABRAMS, S. M. L.
HEIDENDAL, G. A. K. *see* VAN DER MEULEN, J.
HENRY, P. J. *see* GOLDIE, R. G.
HERZ, R. *see* ROSSLE, M.
HIBBERD, S. G., ALVEYN, C., COOMBES, E. J. & HOLGATE, S. T. Acute and chronic pharmacokinetics of assymetrical doses of slow release choline theophyllinate in asthma, 337
HILDEBRANDT, R. *see* GUNDERT-REMY, U.
HOCKINGS, N., PALL, A., MOODY, J., DAVIDSON, A. V. M. & DAVIDSON, D. L. W. The effects of age on carbamazepine pharmacokinetics and adverse effects, 725
HODDER, R. W. *see* NEALE, M. G.
HOEDEMAKER, G. *see* VISSER, C. A.
HOFFMANN, S. *see* RATNAIKE, R. N.
HOLGATE, S. T. *see* CUSHLEY, M. J.
HOLGATE, S. T. *see* HIBBERD, S. G.
HOLLER, L. *see* DUKA, TH.
HOLMBERG, B. *see* NYBERG, G.
HOLT, D. W. *see* ADAMS, P. C.
HORTON, R. W. *see* THEODOROU, A. E.
HOSIE, J. *see* GEORGE, C. F.
HOWES, L. G., MACGILCHRIST, A., HAWSKBY, C., SUMNER, D. & REID, J. L. Plasma [$^3$H]-noradrenaline kinetics and blood pressure following regular, moderate ethanol consumption, 521
HUGHES, A., THOM, S., MARTIN, G., REDMAN, D., HASAN, S. & SEVER, P. The action of dopamine ($DA_1$) receptor agonist, fenoldopam in human vasculature *in vivo* and *in vitro*, 535
HUTCHINGS, A. & ROUTLEDGE, P. A. A simple method for determining acetylator phenotype using isoniazid, 343
HUTCHINGS, A. *see* BENTLEY, D. P.
HUTT, H. J. *see* KIRCH, W.
HUTTON, C. W. *see* COLLINS, A. J.
HYSLOP, R. *see* EDSTEIN, M. D.

IBSEN, M. *see* PETRING, O. U.
IKOMI-KUMM, J. *see* EDVINSSON, L.
IKRAM, H. *see* LOGAN, R. L.
IMAI, Y., INADA, M., TAMURA, S., KAWATA, S., MINAMI, Y. & TARUI, S. Comparative effects of famotidine and cimetidine on 7-ethoxycoumarin *O*-deethylase activity in human livers, 495
INABA, T., TYNDALE, R. E. & MAHON, W. A. Quinidine: potent inhibition of sparteine and debrisoquine oxidation *in vivo*, 199
INADA, M. *see* IMAI, Y.
ISHIZAKI, T. *see* KUBOTA, K.

JACKSON, N. *see* FRAIS, M. A.
JACKSON, N. C. *see* SILKE, B.
JACKSON, P. R., TUCKER, G. T., LENNARD, M. S. & WOODS, H. F. Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices, 541
JAWAD, S., OXLEY, J., YUEN, W. C. & RICHENS, A. The effect of lamotrigine, a novel anticonvulsant on interictal spikes in patients with epilepsy, 191
JAYASINGHE, K. S. A., ROBERTS, C. J. C. & READ, A. E. Is biliary excretion of paracetamol significant in man?, 363
JEREMY, J. Y., BARRADAS, M. A., MIKHAILIDIS, D. P. & DANDONA, P. Effects of verapamil and nisoldipine on human platelets: *in vivo* and *in vitro* studies, 200
JOHNSON, B. F., SHEKAR, V., WOODMAN, T. & CANADA, A. T. Salivary concentrations of pimenol as a possible cause of unpleasant taste, 613
JOHNSON, E. S. *see* DAVIES, I. B.
JONES, C. R. *see* ELLIOTT, H. L.
JONES, D. B. *see* PRICHARD, P. J.
JONES, D. B. *see* ROSSLE, M.
JONES, E. C. *see* FINDLAY, J. W. A.
JONGES, R. *see* VISSER, C. A.
JORDAN, A. *see* NICHOLSON, P. W.
JULIAN, D. Introduction to supplement 3, 191S
JULIAN, D. Closing remarks to supplement 3, 351S

KAIRALUOMA, M. *see* PELKONEN, O.
KALLIO, O. *see* SYVALAHTI, E. K. G.
KALRA, P. A. *see* SILKE, B.
KATONA, C. L. E. *see* THEODOROU, A. E.
KAWATA, S. *see* IMAI, Y.

KEAL, E. E. *see* MORICE, A. M.
KELLY, J. S. *see* THEODOROU, A. E.
KELMAN, A. W. *see* LEES, K. R.
KENNEDY, H. J. *see* HAMDY, N. A. T.
KIERULF, P. *see* BREDESEN, J. E.
KIRBY, M. J. & AGADAH, W. O. The influence of the contraceptive pill on feeding patterns in young women, 247P
KIRCH, W., STENZEL, J., DYLEWCZ, P., HUTT, H. J., SANTOS, S. R. & OHNHAUS, E. E. Influence of nisoldipine on haemodynamic effects and plasma levels of digoxin, 155
KITTERINGHAM, N. R. *see* MAGGS, J. L.
KLOTZ, U., MIKUS, G., ZEKORN, C. & EICHELBAUM, M. Pharmacokinetics of midazolam in relation to polymorphic sparteine oxidation, 619
KLOTZ, U., ZIEGLER, G., ROSENKRANZ, B. & MIKUS, G. Does the benzodiazepine antagonist Ro 15-1788 antagonize the action of ethanol?, 513
KNUDSEN, O. *see* LUND, B.
KOKURINA, E. V. *see* RUMIANTSEV, D. O.
KÖLLE, E. U. & VOLLMER, K.-O. Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers, 135S
KOLLY, M. & PECOUD, A. Comparison of levocabastine, a new selective $H_1$-receptor antagonist, and disodium cromoglycate, in a nasal provocation test with allergen, 389
KOOLEN, J. J. *see* VISSER, C. A.
KRÜDEWAGEN, B. *see* GUNDERT-REMY, U.
KUTZ, K. *see* GREVEL, J.
KUBOTA, K., ISHIZAKI, T., CHIBA, K., TAKAGI, A., NAKAGAWA, A. & NAKAMURA, K. Antipyrine clearance and metabolism in patients with psoriasis, 455
KUHA, K. *see* PELKONEN, O.

LADER, M. & BRUCE, M. States of anxiety and their induction by drugs, 251
LADER, M. *see* BRUCE, M.
LAFERLA, G., BUCHANAN, N., HEARNS, J., CREAN, G. P., MCCOLL, K. E. L. & CLUCAS, A. T. The antisecretory effects of zaltidine, a novel long-acting $H_2$-receptor antagonist, in healthy volunteers and in subjects with a past history of duodenal ulcer, 395
LAHER, M. *see* ARMSTRONG, C.
LAHIRI, A. *see* AL-KHAWAJA, I. M.
LAHIRI, A. *see* RODRIGUES, E. A.
LAMBERT, C. *see* MAGGS, J. L.
LAMBERT, D. *see* WILLIAMS, F. M.
LAMMERS, J. W. J., MÜLLER, M. E. T. M., FOLGERING, H. TH. M. & VAN HERWAARDEN, C. L. A. A comparative study on the ventilatory and haemodynamic effects of xamoterol and atenolol in asthmatic patients, 595
LANGAN, J. J. *see* MURRAY, T. S.
LAU, C. P. *see* MALTZ, M. B.
LAWSON, D. H. Post-marketing surveillance in the UK (1984), 71S
LEE, S. M., WILLIAMS, R., WARNOCK, D., EMMETT, M. & WOLBACH, R. A. The effects of nicardipine in hypertensive subjects with impaired renal function, 297S
LEES, A. J. *see* HARDIE, R. J.
LEES, K. R. & REID, J. L. Effects of the angiotensin converting enzyme inhibitor, perindopril, in hypertensive patients, 210P
LEES, K. R., KELMAN, A. W., MEREDITH, P. & REID, J. L. Pharmacokinetics of the angiotensin converting enzyme inhibitor, perindopril, after repeated oral dosing, 233P
LEES, K. R., KELMAN, A. W. & REID, J. L. Effect of repeated dosing on concentration–effect relationships with the angiotensin converting enzyme inhibitor, perindopril, 234P
LEESER, J. E. *see* WILLIAMS, F. M.
LEGGIERI, E. *see* MIADONNA, A.
LEIGH, P. J. *see* ALT, U.
LELO, A., BIRKETT, D. J., ROBSON, R. A. & MINERS, J. O. Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man, 177
LELO, A., MINERS, J. O., ROBSON, R. A. & BIRKETT, D. J. Quantitative assessment of caffeine partial clearances in man, 183
LENNARD, M. S. *see* JACKSON, P. R.
LEOPOLD, G., UNGETHÜM, W., PABST, J., SIMANE, Z., BÜHRING, K. U. & WIEMAN, H. Pharmacodynamic profile of bisoprolol, a new $\beta_2$-selective adrenoceptor antagonist, 293
LEVISON, N. *see* MURRAY, T. S.
LEWIS, J. G. *see* AL-KHAWAJA, I. M.
LINDBERG, R. *see* SYVALAHTI, E. K. G.
LINDSTRÖM, B. *see* FEDEKE ADEROUNMU, A.
LINDSTRÖM, B. *see* OFORI-ADJEI, D.
LIPKIN, D. P. *see* POOLE-WILSON
LITTLER, W. A., YOUNG, M. A. & SMITH, S. A. The acute and chronic effects of nicardipine on blood pressure, heart rate, neurocirculatory reflexes and renal function in hypertensive patients, 239S
LOCNISKAR, A. *see* ABERNETHY, D. R.
LOFTUS, N. J., NIGHTINGALE, J. M. D. & VERE, D. W. Relationship between plasma theophylline levels following an i.v. dose and those after oral sustained-release theophylline, 242P
LOGAN, R. L., IKRAM, H., WEBSTER, M. W. & GUPPY, W. Comparative efficacy of nicardipine hydrochloride and atenolol in the treatment of chronic stable angina, 345S
LOOAREESUWAN, S., WHITE, N. J., CHANTHAVANICH, P., EDWARDS, G., NICHOLL, D. D., BUNCH, C. & WARRELL, D. A. Cardiovascular toxicity and distribution kinetics of intravenous chloroquine, 31
LORINI, M. *see* MIADONNA, A.
LOUIS, W. J. *see* PRICHARD, P. J.
LULICH, K. M. *see* GOLDIE, R. G.
LUND, B., EGSMOSE, C., KNUDSEN, O. & ANDERSEN, R. B. Pharmacokinetic profile of indoprofen in elderly subjects, 721
LUZIO, S. *see* OWENS, D. R.
LYNAS, A. G. A., CHESTNUTT, W. N., DUNDEE, J. W. & GHALY, R. G. Neiguan, the P6 anti-emetic acupuncture point: effect on nalbuphine emetic sequelae 223P
LYNAS, A. G. A. *see* DUNDEE, J. W.
LYNN, K. L. *see* WOOLNER, D. F.

MACDERMOT, J. *see* ALT, U.

MACGILCHRIST, A. *see* HOWES, L. G.
MAGGS, J. L., LAMBERT, C., KITTERINGHAM, N. R., ORME, M. L'E. & PARK, B. K. Metabolism of phenytoin and ethinolestradiol to reactive metabolites by human liver microsomes, 241P
MAGNOLIA, M. R. *see* VARINO, V.
MAHON, W. A. *see* INABA, T.
MALCOLM, S. L. *see* HARDIE, R. J.
MALLET, A. I. *see* WONG, E.
MALTZ, M. B., DAVIES, D. W., LAU, C. P., CREAMER, J. E., BANIM, S. O. & CAMM, A. J. The effects of oral nitrendipine and propranolol, alone and in combination, on hypertensive patients with special reference to AV conduction, 463
MANTHEY, B. *see* GARRETT, R.
MARCHESI, C. *see* CHIODERA, P.
MARKS, V. *see* BRUCE, M.
MARKS, V. *see* SCOTT, N. R.
MARSHALL, R. W. *see* ABILA, B.
MARTIN, G. *see* HUGHES, A.
MARTINEZ, J. G., MURAKAMI, S. I. & SCHEINBERG, M. A. The effect of isoxicam on neutrophil and monocyte function, 117S
MASSART, P. & BÈZES, H. Comparison of the efficacy and tolerance of isoxicam and piroxicam following surgery for skiing accidents, 161S
MAWER, G. E. *see* RICHARDSON, T.
MCCAFFREY, P. M., RIDDELL, J. G. & SHANKS, R. G. The selectivity of xamoterol as assessed by its effect on sleeping heart rate in the presence and absence of ICI 118,551, 237P
MCCLELLAND, G. R. & RAPTOPOULOS, P. Paroxetine and amylobarbitone: effects on psychomotor performance, 227P
MCCOLL, K. E. L. *see* LAFERLA, G.
MCDEVITT, D. G. Symposium summary (supplement 1), 103S
MCEWEN, J. Contribution of universities to drug evaluation, 15S
MCEWEN, J. *see* CHALLENOR, V.
MCGIBNEY, D. *see* FAULKNER, J. K.
MCINNES, G. T. & BRODIE, M. J. Pharmacokinetics and pharmacodynamics of two oxprenolol oral osmotic (OROS) delivery systems in hypertensive patients, 204P
MCKENNA, E. A. *see* VERBEEK, R. K.
MCMURDO, E. T. *see* CHALLENOR, V.
MEHTA, A. *see* PRICE, D.
MEHTA, A. *see* PRICE, D. E.
MELA, G. S. *see* VARINO, V.
MEREDITH, P. *see* LEES, K. R.
MEREDITH, P. A., ELLIOTT, H. L., VINCENT, J. & REID, J. L. A clinical pharmacological assessment of a new osmotic pump formulation of prazosin, 235P
MEREDITH, P. A. *see* ELLIOTT, H. L.
METELITSA, V. I. *see* RUMIANTSEV, D. O.
MIADONNA, A., TEDESCHI, A., LEGGIERI, E., LORINI, M., FROLDI, M. & ZANUSSI, C. Effect of calcium antagonists on histamine release from human basophil leukocytes, 483
MIDDLETON, H. C. & NUTT, D. J. Are the cardiovascular effects of imipramine centrally mediated?, 221P
MIDDLETON, H. C. *see* NUTT, D. J.
MIDTBO, K. A., SILKE, B., VERMA, S. P., REYNOLDS, G. & TAYLOR, S. H. Haemodynamic dose-response effects of dobutamine and amrinone in acute heart failure, 209P
MIHALY, G. W. *see* PRICHARD, P. J.
MIKHAILIDIS, D. P. *see* JEREMY, J. Y.
MIKUS, G. *see* KLOTZ, U.
MIMRAN, A. & RIBSTEIN, J. Nitrendipine enhances the effect of adrenaline on serum potassium in normal man, 117
MINAMI, Y. *see* IMAI, Y.
MINERS, J. O., GRGURINOVICH, N., WHITEHEAD, A. G., ROBSON, R. A. & BIRKETT, D. J. Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid, 135
MINERS, J. O., ROBSON, R. A. & BIRKETT, D. J. Paracetamol metabolism in pregnancy, 359
MINERS, J. O. *see* LELO, A.
MINESHITA, S. *see* EICHELBAUM, M.
MISTRY, K. *see* WONG, E.
MOLES, K. *see* NICHOLLS, D. P.
MOLYNEUX, S. J. *see* NUTT, D. J.
MONTASTRUC, J. L. *see* DOUSTE-BLAZY, PH.
MONTI, M. *see* EDVINSSON, L.
MOODY, J. *see* HOCKINGS, N.
MORGAN, D. J., PAULL, J. D., WILSON-EVERED, E. & ZICCONE, S. P. Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate, 587
MORICE, A. M., SCHOFIELD, P., KEAL, E. E. & SEVER, P. S. A comparison of the ventilatory, cardiovascular and metabolic effects of salbutamol, aminophylline and vasoactive intestinal peptide formation in normal subjects, 149
MORLEY, A. R. *see* ADAMS, P. C.
MORRIS, P. K. *see* ALT, U.
MORRIS, T. *see* OWENS, D. R.
MORTON, P. *see* NICHOLS, D. P.
MULLEN, K. D. *see* ROSSLE, M.
MÜLLER, M. E. T. M. *see* LAMMERS, J. W. J.
MULLIE, A. *see* TJANDRA-MAGA, T. B.
MURAKAMI, S. I. *see* MARTINEZ, J. G.
MURDOCK, P. J. *see* NUTT, D. J.
MURRAY, G. R. *see* ABRAMS, S. M. L.
MURRAY, S. *see* SPIERS, C. J.
MURRAY, T. S., EAST, B. W. & ROBERTSON, J. I. S. Nicardipine *vs* propranolol in the treatment of essential hypertension: effect on total body elemental composition, 259S
MURRAY, T. S., LANGAN, J. J. & COXHEAD, P. F. A trial comparing nicardipine and cyclopenthiazide K in a group of general practice patients with mild to moderate hypertension, 243S
MURRAY, T. S., LANGAN, J. J., COXHEAD, P. F. & LEVINSON, N. Long-term effects of nicardipine in the treatment of essential hypertension, 249S
MURTAGH, J. G. *see* NICHOLLS, D. P.
MUSTAJOKI, P. *see* TOKOLA, O.
MUTCH, E. *see* WILLIAMS, F. M.

NAKAGAWA, A. *see* KUBOTA, K.
NAKAMURA, K. *see* KUBOTA, K.
NEALE, M. G., BROWN, K., HODDER, R. W. & AUTY,

R. M. The pharmacokinetics of sodium cromoglycate in man after intravenous and inhalation administration, 373
NELSON, E. B., ABERNETHY, D. R., GREENBLATT, D. J. & AMEER, B. Paracetamol absorption from a feeding jejunostomy, 111
NEWMAN, K. *see* EDSTEIN, M. D.
NICHOLL, D. D. *see* LOOARESUWAN, S.
NICHOLL, J. *see* HAMDY, N. A. T.
NICHOLLS, D. P., MOLES, K., GLEADHILL, D. N. S., BOOTH, K., ROWAN, J. & MORTON, P. Comparison of transdermal nitrate and isosorbide dinitrate in chronic stable angina, 15
NICHOLLS, D. P., URTAGH, J. G., SCOTT, M. E., MORTON, P. & SHANKS, R. G. Acute haemodynamic effects of pinacidil in man, 287
NICHOLSON, A. N., PASCOE, P. A., SPENCER, M. B., STONE, B. M., ROEHRS, T. & ROTH, T. Sleep after a transmeridian flight: use of a rapidly eliminated hypnotic (brotizolam), 225P
NICHOLSON, A. N. *see* BRADLEY, C. M.
NICHOLSON, P. W., ROSENTHAL, M., JORDAN, A., O'NEILL, C., DESHMUKH, A. A., DENHAM, M. J. & DOBBS, S. M. Pressure sores: relationship of drug treatment and illness to spontaneous movement during the night, 224P
NICHOLSON, P. W. *see* DICKINS, J.
NICKLESEN, T. *see* DEMISCH, K.
NICOLIN, P. *see* CASIGLIA, E.
NIGHTINGALE, J. J. *see* HAMILTON-FARRELL, M. R.
NIGHTINGALE, J. M. D. *see* LOFTUS, N. J.
NIMMO, G. R. *see* CRITCHLEY, J. A. J. H.
NOTARIANNI, L. J., COLLINS, A. J. & FERRIE, J. E. Clinical pharmacology of D-penicillamine in rheumatoid arthritis, 244P
NUEESCH, E. *see* GREVEL, J.
NUTT, D. J. & MOLYNEUX, S. J. The effect of diazepam on plasma free MHPG (3-methoxy 4-hydroxy phenylglycol) in man, 230P
NUTT, D. J., MIDDLETON, H. C., MURDOCK, P. J., ARKINSTALL, A. Y. & FRANKLIN, M. The neuroendocrine effects of oral imipramine, 222P
NUTT, D. J. *see* MIDDLETON, H. C.
NYBERG, G. & HOLMBERG, B. A dose-response study of sublingual nitroglycerin in angina pectoris patients at sitting rest and bicycle exercise, 211P

OBENG-GYAN, R. *see* DUKA, TH.
O'BRIEN, W. M. Radiological evaluation of erosions: a quantitative method for assessing long-term remittive therapy in rheumatoid arthritis, 173S
OCHS, H. R. *see* ABERNETHY, D. R.
O'DONNELL, M. The media and their influence on public attitudes to drug development and use, 101S
OE, P. L. *see* VAN DER MEULEN, J.
OFORI-ADJEI, D., ERICSSON, O., LINDSTRÖM, B. & SJÖQVIST, F. Protein binding of chloroquine enantiomers and desethylchloroquine, 356
OFORI-ADJEI, D. *see* FU, S.
OHNHAUS, E. E. *see* EICHELBAUM, M.
OHNHAUS, E. E. *see* KIRCH, W.
OLANOFF, L. S. *see* WALLE, T.
OLOFSSON, O. *see* BJERLE, P.
OLSTAD, O. A. & SKJELBRED, P. Comparison of the analgesic effect of a corticosteroid and paracetamol in patients with pain after oral surgery, 437
OMILE, C. *see* SEMPLE, C. G.
O'NEILL, C. *see* NICHOLSON, P. W.
ORME, M. L.'E. *see* GRIMMER, S. F. M.
ORME, M. L.'E. *see* MAGGS, J. L.
ORME, M. L.'E. *see* ROGERS, S. M.
OSWALD, I. & ADAM, K. Effects of paroxetine on human sleep, 97
OSWALD, I. *see* ADAM, K.
OTTON, S. V. *see* BRINN, R.
OUZAN, D. *see* FERRY, N.
OWENS, D. R., VORA, J., MORRIS, T., LUZIO, S., RYDER, R. E. J., ATIEA, J. & HAYES, T. M. The metabolic response to glucagon and glucagon-(1-21)-peptide in normal subjects and non-insulin dependent diabetics, 325
OXLEY, J. *see* JAWAD, S.

PABST, J. *see* LEOPOLD, G.
PACIFICI, G. M., FRANCHI, M., BENCINI, C. & RANE, A. Valpromide inhibits human epoxide hydrolase, 269
PALL, A. *see* HOCKINGS, N.
PARK, B. *see* PRICE, D.
PARK, B. K. *see* CHOONARA, I. A.
PARK, B. K. *see* COLEMAN, J. W.
PARK, B. K. *see* HAYNES, B. P.
PARK, B. K. *see* PRICE, D. E.
PARK, S. S. *see* PELKONEN, O.
PARNELL, L. *see* WALLER, P. C.
PASANEN, M. *see* PELKONEN, O.
PASCOE, P. A. *see* NICHOLSON, A. N.
PATAMASUCON, P. *see* WANWIMOLRUK, S.
PATERSON, J. W. *see* GOLDIE, R. G.
PATERSON, K. R. *see* SEMPLE, C. G.
PAULL, J. D. *see* MORGAN, D. J.
PAYKEL, E. S. *see* THEODOROU, A. E.
PEACE, K. E. *see* RANDOLPH, W. C.
PEARSON, R. M. *see* CASSIDY, S. L.
PECOUD, A. *see* KOLLY, M.
PEDERSEN, S. *see* STEFFENSEN, G.
PELKONEN, O., PASANEN, M., KUHA, H., GACHALYI, B., KAIRALUOMA, M., SOTANIEMI, E. A., PARK, S. S., FRIEDMAN, F. K. & GELBOIN, H. V. The effect of cigarette smoking on 7-ethoxyresorufin *O*-deethylase and other monooxygenase activities in human liver: analyses with monoclonal antibodies, 125
PERCARIO, G. *see* VARINO, V.
PERRY, J. L. *see* FAULKNER, J. K.
PESSINA, A. C. *see* CASIGLIA, E.
PETRIE, J. C. *see* SCOTT, A. K.
PETRING, O. U., ADELHØJ, B., IBSEN, M. & POULSEN, H. E. The relationship between gastric emptying of semisolids and paracetamol absorption, 659
PIANEZZOLA, E. *see* DE PAOLIS, C.
PIETERS, F. A. J. M. & ZUIDEMA, J. The pharmacokinetics of dapsone after oral administration to healthy volunteers, 491
PILCHER, J. *see* CHORARIA, S. K.
PINTO, O. DE S. Organisation and problems of drug evaluation in multicentre clinical trials, 49S
PIOTROVSKII, V. K. *see* RUMIANTSEV, D. O.
PONGMARUTAI, M. *see* WANWIMOLRUK, S.

PONTIROLI, A. E. *see* DE PAOLIS, C.
POOLE-WILSON, P. A. The role of nicardipine in the treatment of angina pectoris—chairman's comments, 307S
POOLE-WILSON, P. A. & LIPKIN, D. P. Lack of negative inotropic effect on heart muscle following infusion of nicardipine into patients with coronary artery disease. Effects of atrial pacing, 309S
POSNER, J. *see* FINDLAY, J. W. A.
POSTON, J. W. *see* STEVENS, J. C.
POULEUR, H. *see* HANET, C.
POULSEN, H. E. *see* PETRING, O. U.
PRESCOTT, L. F. *see* CRITCHLEY, J. A. J. H.
PRICE, D., MEHTA, A., PARK, B., HAY, A. & FEELY, M. The effect of low dose phenobarbitone on three indices of hepatic microsomal enzyme induction, 218P
PRICE, D. E., MEHTA, A., PARK, B. K., HAY, A. & FEELY, M. P. The effect of low-dose phenobarbitone on three indices of hepatic microsomal enzyme induction, 744
PRICHARD, P. J., JONES, D. B., YEOMANS, N. D., MIHALY, G. W., SMALLWOOD, R. A. & LOUIS, W. J. The effectiveness of ranitidine in reducing gastric acid secretion decreases with continued therapy, 663
PRINGLE, T. H., FRANCIS, R. J., EAST, P. B. & SHANKS, R. G. Pharmacodynamic and pharmacokinetic studies on bufuralol in man, 527
PUGH, S. E. *see* BOON, N. A.
PURDIE, G. *see* RATNAIKE, R. N.

RAFTERY, E. B. *see* AL-KHAWAJA, I. M.
RAFTERY, E. B. *see* RODRIGUES, E. A.
RAMSAY, L. E. *see* CAMERON, H. A.
RAMSAY, L. E. *see* WALLER, P. C.
RANDOLPH, W. C., SEAMAN, J. J., DICKSON, B., PEACE, K. E., FRANK, W. O. & YOUNG, M. D. The effect of age on theophylline clearance in normal subjects, 603
RANE, A. *see* PACIFICI, G. M.
RAPEPORT, W. G., ARONSON, J. K., GRAHAME-SMITH, D. G. & HARPER, C. The effects of serum, lithium, ethacrynic acid, and a low external concentration of potassium on specific [$^3$H]-ouabain binding to human lymphocytes after incubation for 3 days, 275
RAPTOPOULOS, P. *see* MCCLELLAND, G. R.
RATNAIKE, R. N., SCHAPEL, G. J., PURDIE, G., RISCHBIETH, R. H. C. & HOFFMAN, S. Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs, 100
RAWLINS, M. D. *see* WILLIAMS, F. M.
RAWTHORNE, A. *see* WHITCROFT, I.
READ, A. E. *see* JAYASINGHE, K. S. A.
REDMAN, D. *see* HUGHES, A.
REID, J. L. *see* AJAYI, A. A.
REID, J. L. *see* DONNELLY, R.
REID, J. L. *see* ELLIOTT, H. L.
REID, J. L. *see* HAMILTON, C. A.
REID, J. L. *see* HOWES, L. G.
REID, J. L. *see* LEES, K. R.
REID, J. L. *see* MEREDITH, P. A.
REID, P. G. *see* WATT, A. H.
REIJN, E. *see* VAN DER MEULEN, J.
REILLY, A., BROWN, D., TAYLOR, R. J. & WEBSTER, J. Evaluation of the influence of the 'limited list' scheme on stock orders for prescribed drugs in a retail pharmacy, 246P
RENWICK, A. G. *see* CHALLENOR, V.
RENWICK, A. G. *see* GEORGE, C. F.
REYNOLDS, G. *see* FRAIS, M. A.
REYNOLDS, G. *see* MIDTBA, K. A.
REYNOLDS, G. *see* SILKE, B.
REYNOLDS, G. W. *see* SILKE, B.
RIBSTEIN, J. *see* MIMRAN, A.
RICHARDSON, T., FOSTER, J. & MAWER, G. E. Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide—drug interaction or summation of similar effects, 43
RICHENS, A. *see* ABILA, B.
RICHENS, A. *see* JAWAD, S.
RIDDELL, J. G. *see* DEERING, A. H.
RIDDELL, J. G. *see* MCCAFFREY, P. M.
RIETH, R. *see* DEMISCH, K.
RISCHBIETH, R. H. C. *see* RARNAIKE, R. N.
ROATH, O. S. *see* WALLER, D. G.
ROBERTS, C. J. C. *see* JAYASINGHE, K. S. A.
ROBERTS, D. H., TSAO, Y. & BRECKENRIDGE, A. M. The effects of four anti-hypertensive agents upon haemodynamics at rest and after exercise in hypertensive patients, 206P
ROBERTS, D. H. *see* COLEMAN, J. W.
ROBERTSON, J. I. S. The treatment of hypertension, 237S
ROBERTSON, J. I. S. *see* MURRAY, T. S.
ROBSON, R. A. *see* LELO, A.
ROBSON, R. A. *see* MINERS, J. O.
RODRIGUES, E. A., AL-KHAWAJA, I. M., LAHIRI, A. & RAFTERY, E. B. Calcium antagonist treatment and its effect on left ventricular function in patients with ischaemic heart disease, 319S
ROEHRS, T. A., ZORICH, F. J., WITTIG, R. M. & ROTH, T. Dose determinants of rebound insomnia, 143
ROEHRS, T. *see* NICHOLSON, A. N.
ROGERS, S. M., BACK, D. J. & ORME, M. L.'E. Metabolism of paracetamol in small intestine and colon, 217P
RONCARNI, G., ZIEGLER, W. H. & GUENTERT, T. W. Pharmacokinetics of the new benzodiazepine Ro 15-1788 in man following intravenous and oral administration, 421
ROSENKRANZ, B. *see* KLOTZ, U.
ROSENTHAL, J. *see* NICHOLSON, P. W.
ROSENTHALER, J. *see* GREVEL, J.
ROSS, S. G. *see* VERBEEK, R. K.
ROSSI, G. *see* CHIODERA, P.
RÖSSLE, M., HERZ, R., MULLEN, K. D. & JONES, D. B. The disposition of intravenous L-tryptophan in healthy subjects and in patients with liver disease, 633
ROTH, T. *see* NICHOLSON, A. N.
ROTH, T. *see* ROEHRS, T. A.
ROUSSEAU, M. F. *see* HANET, C.
ROUTLEDGE, P. A. The plasma binding of basic drugs, 499

ROUTLEDGE, P. A. *see* BENTLEY, D. P.
ROUTLEDGE, P. A. *see* HUTCHINGS, A.
ROUTLEDGE, P. A. *see* WATT, A. H.
ROUTLEDGE, P. A. *see* WILLIAMS, P. E.
ROUX, H. *see* DOURY, P.
ROWAN, J. *see* NICHOLLS, D. P.
RUMIANTSEV, D. O., PIOTROVSKII, V. K., RIABOKON, O. S., SLASTNIKOVA, I. D., KOKURINA, E. V. & METELITSA, V. I. The effect of oral verapamil therapy on antipyrine clearance, 606
RYDER, R. E. J. *see* OWENS, R. E. J.

SALATI, G. *see* CHIODERA, P.
SALAKO, L. A. *see* FADEKE ADEROUNMU, A.
SANTOS, S. R. *see* KIRCH, W.
SASSARD, J. *see* FERRY, N.
SCALABRINI, P. *see* VARINO, V.
SCHAPEL, G. J. *see* RATNAIKE, R. N.
SCHEINBERG, M. A. *see* MARTINEZ, J. G.
SCHÖFFLING, K. *see* DEMISCH, K.
SCHOFIELD, P. *see* MORICE, A. M.
SCOTT, A. K., WEBSTER, J., PETRIE, J. C., FAULKNER, J. K. & COLLIER, J. Sorbinil pharmacokinetics in male and female elderly volunteers, 241P
SCOTT, N. R., CHAKRABORTY, J. & MARKS, V. Urinary metabolites of caffeine in pregnant women, 517
SCOTT, M. E. *see* NICHOLLS, D. P.
SCOTT, N. *see* BRUCE, M.
SEAMAN, J. J. *see* RANDOLPH, W. C.
SEDDON, C. E. *see* SPEIRS, C. J.
SEMPLE, C. G., OMILE, C., BUCHANAN, K. D., BEASTALL, G. H. & PATERSON, K. R. Effect of oral verapamil on glibenclamide stimulated insulin secretion, 187
SEMPLICINI, A. *see* CASIGLIA, E.
SEVER, P. *see* HUGHES, A.
SEVER, P. S. *see* MORICE, A. M.
SEYMOUR, D. *see* DAVIES, I. B.
SHADER, R. I. *see* ABERNETHY, D. R.
SHADER, R. I. *see* FRIEDMAN, H.
SHANKS, R. G. *see* DEERING, A. H.
SHANKS, R. G. *see* MCCAFFREY, P. M.
SHANKS, R. G. *see* NICHOLLS, D. P.
SHANKS, R. G. *see* PRINGLE, T. H.
SHARMA, S. *see* FRAIS, M. A.
SHEKAR, V. *see* JOHNSON, B. F.
SHENFIELD, G. M. *see* SUHARDJONO, D.
SHEPPEARD, H. & COUCHMAN, K. G. Experience with isoxicam and catabolin, 121S
SIEBERT-WEIGEL, M. *see* CALDWELL, J.
SILKE, B., FRAIS, M. A., VERMA, S. P., REYNOLDS, G. W., HAFIZULLAH, M., KALRA, P. A., JACKSON, N. C. & TAYLOR, S. H. Comparative haemodynamic effect of intravenous lignocaine, disopyramide and flecainide in uncomplicated acute myocardial infarction, 707
SILKE, B., FRAIS, M. A., VERMA, S. P., REYNOLDS, G., TAYLOR, S. H. & JACKSON, N. C. A review of the haemodynamic effects of nicardipine in ischaemic heart disease, 203S
SILKE, B., VERMA, S. P., FRAIS, M. A., REYNOLDS, G. & TAYLOR, S. H. A rest and haemodynamic evaluation of a new cardioselective β-adrenoceptor blocker celiprolol alone and in combination with nitroglycerine in ischaemic heart disease, 697
SILKE, B. *see* FRAIS, M. A.
SILKE, B. *see* MIDTBO, K. A.
SIMANE, Z. *see* LEOPOLD, G.
SIMPSON, K. H., GREEN, J. H. & ELLIS, F. R. Effect of glycopyrrolate and atropine on thermoregulation after exercise, 579
SINCLAIR, A. J. *see* DAVIES, I. B.
SJÖQVIST, F. & BOETHIUS, G. Attitudes to development of drug therapy in Scandinavia, 19S
SJÖQVIST, F. *see* FU, S.
SJÖQVIST, F. *see* OFORI-ADJEI, D.
SKJELBRED, P. *see* OLSTAD, O. A.
SLASTNIKOVA, I. D. *see* RUMIANTSEV, D. O.
SLAY, L. *see* BROWN, S. T.
SLOAN, P. *see* ADAMS, P. C.
SMALLWOOD, R. A. *see* PRICHARD, P. J.
SMITH, S. A. *see* LITTLER, W. A.
SMITH, S. E. *see* BITTINER, S. B.
SNELL, E. S. Profitability and improved patient care—industry's viewpoint, 33S
SOMMERS, D. *see* VAN WYK, M.
SOTANIEMI, E. A. *see* PELKONEN, O.
SPENCER, M. B. *see* NICHOLSON, A. N.
SPEIRS, C. J., MURRAY, S., BOOBIS, A. R., SEDDON, C. E. & DAVIES, D. S. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine, 739
SPINA, D. *see* GOLDIE, R. G.
SPRAAG, B. *see* BENTLEY, D. P.
STAIB, A. H. *see* CALDWELL, J.
STEFFENSEN, G. & PEDERSEN, S. Food induced changes in theophylline absorption from a once-a-day theophylline product, 574
STEIMER, J. L. *see* GREVEL, J.
STENZEL, J. *see* KICH, W.
STEPHENS, M. R. *see* WATT, A. H.
STERN, G. G. *see* HARDIE, R. J.
STEVENS, J. C., POSTON, J. W., WALKER, S. R. & VANDENBURG, M. J. Is quality of life important and measurable during clinical evaluation?, 245P
STEVENSON, I. H. *see* CONNACHER, A. A.
STEYN, A. G. W. *see* VAN WYK, G.
STONE, B. M. *see* NICHOLSON, A. N.
STROLIN-BENEDETTI, M. *see* CALDWELL, J.
STRUTHERS, A. D. *see* BECKER, R. H. A.
SUHARDJONO, D., BOUTAGY, J. & SHENFIELD, G. M. The effect of glucose on acetylation status, 401
SULLENS, C. M. *see* DICKINS, J.
SUMNER, D. *see* HOWES, L. G.
SUNBHANICH, M. *see* WANWIMOLRUK, S.
SWIET, C. G. *see* WATT, A. H.
STYVALAHTI, E. K. G., LINDBERG, R., KALLIO, J. & DE VOCHT, M. Inhibitory effects of neuroleptics on debrisoquine oxidation in man, 89

TAKAGI, A. *see* KUBOTA, K.
TAMURU, S. *see* IMAI, Y.
TARUI, S. *see* IMAI, Y.
TAYLOR, D. *see* CHORARIA, S. K.
TAYLOR, I. W. *see* FAULKNER, J. K.
TAYLOR, R. J. *see* REILLY, A.
TAYLOR, S. H. *see* FRAIS, M. A.
TAYLOR, S. H. *see* MIDTBA, K. A.
TAYLOR, S. H. *see* SILKE, B.

TEDESCHI, A. *see* MIADONNA, A.
TEELING-SMITH, G. The economics of drug development and use, 45S
TENHUNEN, R. *see* TOKOLA, O.
TERRY, V. G. *see* DICKINS, J.
THEODOROU, A. E., HALE, A. S., DAVIES, S. L., KATONA, C. L. E., YAMAGUCHI, Y., HORTON, R. W., KELLY, J. S. & PAYKEL, E. S. Platelet binding of [$^3$H]-UK-14,304, an $\alpha_2$-adrenoceptor agonist ligand, in depression, 215P
THOM, S. *see* HUGHES, A.
THOMAS, J. *see* WHITCROFT, I.
TJANDRA-MAGA, T. B., VAN MELLE, P., VERBESSELT, R. & DE SCHEPPER, P. J. Altered pharmacokinetics of oral flecainide by cimetidine, 108
TJANDRA-MAGA, T. B., VERBESSELT, R., VAN HECKEN, A., MULLIE, A. & DE SCHEPPER, P. J. Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man, 309
TJIA, J. *see* GRIMMER, S. F. M.
TOKOLA, O., TENHUNEN, R., VOLIN, L. & MUSTAJOKI, P. Pharmacokinetics of intravenously administered haem arginate, 331
TREPO, C. *see* FERRY, N.
TRIGER, D. R. *see* HAMDY, N. A. T.
TSAO, Y. *see* ROBERTS, D. H.
TUCKER, G. T. *see* JACKSON, P. R.
TURNER, P. Profitability and improved patient care—the physician's viewpoint, 41S
TURNER, P. Clinical pharmacology and its implications in everyday practice, 193S
TURNER, P. *see* ABRAMS, S. M. L.
TYNDALE, R. E. *see* INABA, T.

UNGETHÜM, W. *see* LEOPOLD, G.

VALZELLI, G. *see* DE PAOLIS, C.
VAN DER MEULEN, J., REIJN, E., HEIDENDAL, G. A. K., OE, P. L. & DONKER, A. J. M. Comparison of the effects of penbutolol and propranolol on glomerular filtration rate in hypertensive patients with impaired renal function, 469
VAN HECKEN, A. *see* TJANDRA-MAGA, T. B.
VAN MELLE, P. *see* TJANDRA-MAGA, T. B.
VAN WYK, M., SOMERS, D. & STEYN, A. G. W. The influence of loperamide on oro-caecal transit time, 372
VANDENBURG, M. J. *see* STEVENS, J. C.
VAN HERWAARDEN, C. L. A. *see* LAMMERS, J. W. J.
VAN HERWAARDEN, C. L. A. *see* WIJNANDS, W. J. A.
VAN MARLE, W. *see* GEORGE, C. F.
VAN WEZEL, H. B. *see* VISSER, C. A.
VARINO, V., MELA, G. S., SCALABRINI, P., DI TIMOTEO, E., MAGNOLIA, M. R., PERCARIO, G. & CELLE, G. Famotidine and ranitidine control of 24 h intragastric acidity after single bedtime administration: a study using continuous pH monitoring, 749
VEENENDAAL, R. J. *see* EDSTEIN, M. D.
VERBEEK, R. K., ROSS, S. G. & MCKENNA, E. A. Excretion of trazodone in breast milk, 367
VERBESSELT, R. *see* TJANDRA-MAGA, T. B.
VERE, D. W. *see* LOFTUS, N. J.
VERMA, S. P. *see* FRAIS, M. A.
VERMA, S. P. *see* MIDTBA, K. A.
VERMA, S. P. *see* SILKE, B.
VERNON-ROBERTS, B. *see* GARRETT, R.
VINCENT, J. *see* MEREDITH, P. A.
VINCENT, M.-F. *see* HANET, C.
VISSER, C. A., KOOLEN, J. J., VAN WEZEL, H. B., JONGES, R., HOEDEMAKER, G. & DUNNING, A. J. Effects of intracoronary nicardipine and nifedipine on left ventricular function and coronary sinus blood flow, 313S
VOLIN, L. *see* TOKOLA, O.
VOLLMER, K.-O. *see* KOLLE, E. U.
VOLPI, R. *see* CHIODERA, P.
VORA, J. *see* OWENS, D. R.
VREE, T. B. *see* WIJNANDS, W. J. A.

WADE, O. L. Aspects of drug use and safety, 65S
WADE, O. L. Personal tribute to Jim Crooks, 105S
WAHLIN, B. *see* FU, S.
WALKER, O. *see* FADEKE ADEROUNMU, A.
WALKER, S. R. *see* STEVENS, J. C.
WALLER, D. G., CHALLENOR, V. F., FRANCIS, D. A. & ROATH, O. S. Clinical and rheological effects of nifedipine in Raynaud's phenomenon, 449
WALLER, D. G. *see* CHALLENOR, V.
WALLER, P. C., PARNELL, L. & RAMSAY, L. E. Factors predisposing to acute gout in diuretic-treated hypertension, 205P
WALLE, T., WALLE, U. K., OLANOFF, L. S. & CONRADI, E. C. Partial metabolic clearances as determinants of oral bioavailability of propranolol, 317
WALLE, U. K. *see* WALLE, T.
WANWIMOLRUK, S., SUNBHANICH, M., PONGMARUTAI, M. & PATAMASUCON, P. Effects of cimetidine and ranitidine on the pharmacokinetics of quinine, 346
WARNOCK, D. *see* LEE, S. M.
WARRELL, D. A. *see* LOOAREESUWAN, S.
WARRINGTON, S. J. *see* DAVIES, I. B.
WATT, A. H., REID, P. G., STEPHENS, M. R. & ROUTLEDGE, P. A. Adenosine-induced respiratory stimulation depends on site of infusion. Evidence for an action on the carotid body?, 238P
WATT, A. H., BAYER, A. J., SWIFT, C. G. & ROUTLEDGE, P. A. Comparison of respiratory and heart rate effects of intravenous adenosine in young and elderly healthy adults, 239P
WEATHERLEY, B. C. *see* FINDLAYU, J. W. A.
WEBSTER, J. *see* REILLY, A.
WEBSTER, J. *see* SCOTT, A. K.
WEBSTER, M. W. *see* LOGAN, R. L.
WEE, L. H. *see* CUSHLEY, M. J.
WEIL, A. *see* CALDWELL, J.
WEISS, M. Metabolic residence time: influence of the first-pass effect, 121
WELCH, R. M. *see* FINDLAY, J. W. A.
WESTERHOLM, B. Therapeutic auditing at national and international level, 55S
WHITCROFT, I., THOMAS, J., DAVIES, I. B., WILKINSON, N. & RAWTHORNE, A. Calcium antagonists do not impair long-term glucose control in hypertensive non-insulin dependent diabetics (NIDDS), 208P
WHITCROFT, I., WILKINSON, N., RAWTHORNE, A.,

THOMAS, J. & DAVIES, I. B. β-Adrenoceptor antagonists impair long-term glucose control in hypertensive diabetics: role of $\beta_1$-adrenoceptor selectivity and lipid solubility, 236P
WHITE, N. J. *see* LOOAREESUWAN, S.
WHITEHEAD, A. G. *see* MINERS, J. O.
WHITEHOUSE, M. W. Oxicams: relative safety and anti-injury effects in rats, 111S
WHITTINGTON, J. R. *see* AL-KHAWAJA, I. M.
WIEMAN, H. *see* LEOPOLD, G.
WIJNANDS, W. J. A., VREE, T. B. & VANHERWAARDEN, C. L. A. The influence of quinolone derivatives on theophylline clearance, 677
WILKINS, A. J. *see* ALT, U.
WILKINSON, N. *see* WHITCROFT, I.
WILLIAMS, F. M., LEESER, J. E. & RAWLINS, M. D. Pharmacodynamics and pharmacokinetics of single doses of ketanserin and propranolol alone and in combination in healthy volunteers, 301
WILLIAMS, F. M., MUTCH, E., WOODHOUSE, K. W., LAMBERT, D. & RAWLINS, M. D. Ethoxyresorufin *O*-deethylation by human liver microsomes, 263
WILLIAMS, P. E., ALWAZIR, Y. A., ROUTLEDGE, P. A. & CAMPBELL, I. A. Steady-state pharmacokinetics and effects of a new once-daily, slow-release theophylline capsule preparation in asthma, 383
WILLIAMS, S. J. & FARRELL, G. C. Inhibition of antipyrine metabolism by interferon, 610
WILLIAMS, R. *see* LEE, S. M.
WILSON, J. F. *see* ABILA, B.
WILSON-EVERED, E. *see* MORGAN, D. J.
WINTER, D. *see* WOOLNER, D. F.
WITTIG, R. M. *see* ROEHRS, T. A.
WOLBACH, R. A. *see* LEE, S. M.
WONG, E., BARR, R. M., CUNNINGHAM, F. M., MISTRY, K., WOOLLARD, P. M., MALLET, A. I. & GREAVES, M. W. Topical steroid treatment reduces arachidonic acid and leukotriene $B_4$ in lesional skin of psoriasis, 627
WOODHOUSE, K. W. *see* WILLIAMS, F. M.
WOODMAN, T. *see* JOHNSON, B. F.
WOODS, H. F. *see* JACKSON, P. R.
WOOLHOUSE, N. M. *see* CRITCHLEY, J. A. J. H.
WOOLLARD, P. M. *see* WONG, E.
WOOLNER, D. F., WINTER, D., FRENDIN, T. J., BEGG, E. J., LYNN, K. L. & WRIGHT, G. J. Renal failure does not impair the metabolism of morphine, 55
WRIGHT, G. J. *see* WOOLNER, D. F.

YAMAGUCHI, Y. *see* THEODOROU, A. E.
YEATS, D. A. *see* BAKHLE, Y. S.
YEOMANS, N. D. *see* PRICHARD, P. J.
YEUNG, J. H. K. *see* COLEMAN, J. W.
YOUNG, M. A. *see* LITTLER, W. A.
YOUNG, M. D. *see* RANDOLPH, W. C.
YUEN, W. C. *see* JAWAD, S.

ZANUSSI, C. *see* MIADONNA, A.
ZEKORN, C. *see* EICHELBAUM, M.
ZEKORN, C. *see* KLOTZ, U.
ZICCONE, S. P. *see* MORGAN, D. J.
ZIEGLER, G. *see* KLOTZ, U.
ZIEGLER, W. H. *see* RONCARNI, G.
ZORICK, F. J. *see* ROEHRS, T. A.
ZUIDEMA, J. *see* PIETERS, F. A. J. M.

# SUBJECT INDEX

(S = supplement; P = proceedings)


α-adrenoceptors, 623
$\alpha_2$-adrenoceptor agonist, 215P
α-adrenoceptor antagonist, 231P
Absorption, 111, 421
Acetylation, 401
Acetylator phenotype, 343
Acipimox, 496
Acupuncture, 214P, 223P
Acute inflammation, 121S
Adenosine, 238P, 239P, 685
Adimolol, 235P
Adrenaline, 117
Adverse drug reaction, 83S
Age, 129S, 149S, 289S, 603, 725
Alfuzosin, 231P
Algorithms, 37
Allergic rhinitis, 389
Aluminium hydroxide, 309
Aminophylline, 149
Amiodarone, 736
Amlodipine, 21, 232P
Ammonia, 100
Amrinone, 209P
Amylobarbitone, 227P
Analgesia, 437
Analgesics, 226P
Angina, 114, 115, 211P, 307S, 319S, 325S, 339S, 345S
Angiotensin II, 409
Angiotensin converting enzyme activity, 283S
Angiotensin converting enzyme inhibitor, 167, 210P, 233P, 234P, 409
Ankylosing spondolytis, 157S
Anti-inflammatory, 111S
Anti-inflammatory drugs, 243P
Antibodies, 161
Anticholinergic drugs, 579
Antiepileptic, 191
Antihistamine, 715, 718
Antipyrine, 218P, 224P, 49, 606, 744
Antipyrine clearance, 610
Antipyrine metabolites, 455
Anxiety, 251
Arachidonic acid, 213P, 627
Aryl hydrocarbon hydroxylase, 455
Aspirin, 125S, 135, 443
Asthma, 337, 383, 487, 595, 669
Atenolol, 206P, 345S, 595

β-adrenoceptor agonists, 669
β-adrenoceptor antagonist, 235P, 527, 236P
β-adrenoceptor blockade,
β-adrenoceptor blocker, 691, 697
β-adrenoceptors, 104
β-carbolines, 251
$\beta_1$-adrenoceptor antagonist, 293
$\beta_1$-adrenoceptor function, 595
Baroreflex, 339S
Basic drugs, 499
Basophil leukocytes, 483
Benzodiazepine antagonist, 421, 513
Benzodiazepine receptor antagonist, 228P
Bile, 363
Bioavailability, 135S, 309
Biotransformation, 195S
Bisopropol, 293
Blood pressure, 167, 521
Blood vessels, 535
Breast milk, 367, 733
Brotizolam, 225P
Bufuralol, 527

C-peptide, 187
Caffeine, 81, 177, 183, 251, 475
Calcium antagonist, 187, 208P, 273S, 483
Calcium channel blockade, 213S
Captopril, 161, 206P, 409
Carbachol, 669
Carbamazepine, 725
Carbon dioxide, 149
Cardiovascular toxicity, 31
Cartilage, 121S
Catabolin, 121S
Catecholamines, 149
Cation transport, 27
Celiprolol, 697
Chemotaxis, 117S
Chloroquine, 31, 93, 356, 559, 733
Chlorpropamide, 43
Cholestyramine, 496
Cigarette smoking, 125
Cilazapril, 167
Cimetidine, 108, 346, 495
Ciprofloxacin, 677
Cirrhosis, 643
Clinical pharmacology: the interface between medicine and the pharmaceutical industry, supplement 1, 1S
Clomipramine, 216P
Codeine, 61, 226P, 507
Coeliac disease, 217P
Cognitive assessment, 267S
Cognitive tests, 81
Collagen, 443
Colon, 217P
Comparative trial, 15
Compliance, 246P
Conjugation, 649
Contraceptive pill, 247P
Contraceptive steroids, 135
Coronary artery disease, 303S, 309S
Coronary haemodynamics, 215S
Coronary sinus blood flow, 313S
Cortisol, 620
Cyclopenthiazide-K, 243S

Cyclophosphamide, 173S
Cyclosporin A, 220P
Cytochrome P-450, 125

Danes, 415
Dapsone, 491, 733
Debrisoquine, 89, 199, 739
Dental anaesthesia, 212P
Depression, 215P, 620
Desensitization, 118
Desethylchloroquine, 93, 356
Desipramine, 73
Developing countries, 27S
D-Glucaric acid, 218P, 744
Diabetes, 208P, 236P, 401
Diazepam, 230P, 642
Diet, 649
Digoxin, 27, 155, 752
Disopyramide, 281, 707
Disposition, 61, 421
Diuretics, 205P
Dobutamine, 209P
Domperidone, 479
Dopamine agonist, 1
Dopamine receptor, 535
Dose dumping, 571
Dose effects, 143
Drug development, 3S, 19S, 31S, 45S, 101S
Drug evaluation, 9S, 49S
Drug hypersensitivity, 161
Drug metabolism, 135, 177, 183, 359, 401, 610
Drug oxidation, 415
Drug regulation, 67S
Drug research, 3S, 5S
Drug therapy, 19S
Dysrhythmias, 212P

Elderly subjects, 721
Electrolytes, 259S
Enalapril, 283S, 752
Enantiomers, 242P
Enantiomers of chloroquine, 93
Endocrine, 231S
Enoxacin, 677
Enoximone, 209P
Enzyme induction, 49, 218P, 744
Enzyme inhibition, 606
Epoxide hydroxylase, 269
Ergoline, 1
Erythrocyte ammonia, 100
Eskimos, 415
Ethacrynic acid, 275
Ethanol, 513, 521
Ethnic differences, 415, 649
7-Ethoxycoumarin *O*-deethylase, 495
Ethoxyresorufin, 263
Ethinyloestradiol, 217P, 241P
Excretion, 363
Exercise, 104

Famotidine, 495, 749
Fenofibrate, 219P
Fenoldopam, 535

First pass effect, 121
Flecainide, 108, 309, 707
Fluvoxamine, 620
Food, 309, 565, 571
Forearm blood flow, 535

Gas chromatography, 55
Gastric acid, 663
Gastric emptying, 659
Gastroscopy, 643
Gastrotoxicity, 111S
Genetic polymorphism, 194, 415
Glibenclamide, 187
Glipizide, 240P
Glomerular filtration rate, 469
Glucagon, 187, 325
Glucagon-(1,21)-peptide, 325
Glucose, 187, 236P
Glucuronidation, 359
Glycosaminoglycan, 121S
Gout, 205P
Greenlanders, 415

$H_1$-receptor antagonist, 718
$H_2$-receptor antagonist, 395, 495, 749
Haem arginate, 331
Haemin, 331
Haemodynamics, 203S, 287, 309S, 707
Haemopexin, 331
Halothane, 212P
Heart failure, 209P
Heat production rate, 685
Heat stress, 579
Hepatic function, 100
Hepatic insufficiency, 143S
Hepatic microsomal monooxygenase, 455
Hepatitis B, 610
Histamine, 669
Histamine release, 483
Hormonal response, 325
Human bronchus, 669
6-β-hydroxycortisol, 218P, 744
12-hydroxyeicosatetraenoic acid, 627
4-hydroxylation, 739
5-hydroxytryptamine, 487
Hypertension, 204P, 205P, 206P, 210P, 236P, 237S, 243S, 249S, 259S, 273S, 283S, 289S, 297S, 339S, 469
Hypnotic, 643, 715
Hypoglycaemia, 43

ICI 118, 551, 273P
Iloprost, 118
Imipramine, 221P, 222P
Impaired renal function, 469
*In vitro* test, 93
Indoprofen, 721
Indoramin, 231P
Inflammation, 243P
Inhalation, 373
Inhibition, 739
Inotropism, 309S
Insomnia, 143

Insulin, 187
Interaction, 108, 121S, 155, 301, 346, 496, 513, 677, 752
Interferon, 610
Interictal spikes, 191
Intracoronary, 313S
Ischaemic heart disease, 697
Isoniazid, 343
Isoxicam supplement, 107S
Isoxicam, 111S, 117S, 121S, 125S, 129S, 135S, 143S, 149S, 157S, 161S, 167S

Jejunostomy, 111

Ketanserin, 114, 301, 750
Ketoprofen, 157S
Kidney, 297S
Kidney failure, 55

Labetalol, 206P
Lactation, 367
Lamotrigine, 191
Left ventricular function, 203S, 273S, 309S, 313S, 319S
Leukotriene B4, 627
Levocabastine, 389
Levodopa, 429
Lignocaine, 707
Limited list, 246P
Lithium, 275
Liver, 495
Liver disease, 633
Liver drug metabolism, 125
Liver microsomes, 263
Long-term efficacy, 249S
Loperamide, 371, 372
Lorazepam, 229P
Lung, 213P

Mass fragmentography, 55
Media, 101S
Melatonin, 73, 620
Metabolic, 321S
Metabolic activation, 649
Metabolic effects, 149
Metabolic response, 325
Metabolism, 89, 317, 475
Metabolites, 81
3-Methoxy 4-hydroxy-phenylglycol, 230P
Methylprednisolone, 437
Methylxanthines, 177
Metoclopramide, 479
Metoprolol, 541, 750
Microcalorimetry, 685
Midazolam, 619, 643
Monoclonal antibodies, 125
Morphine, 55
Multicentre clinical trials, 49S
Multiple dosing kinetics, 721
Myocardial metabolism, 215S

Nadolol, 119
Nalbuphine, 223P
Nalidixic acid, 677
Naproxen, 167S
Nausea, 507
Neuroleptics, 89
Neutrophil inclusions, 736
Nicardipine, 195S, 203, 203S, 215S, 231S, 234, 239S, 243S, 249S, 259S, 267S, 273S, 283S, 289S, 297S, 307S, 309S, 313S, 319S, 325S, 331S, 339S, 345S
Nicardipine: a new calcium antagonist, supplement 3, 191S
Nifedipine, 208P, 240P, 313S, 325S, 449, 565
Nisoldipine, 155, 201
Nitrazepam, 551
Nitrendipine, 117, 463
Nitroglycerin, 211P, 697
Nitroprusside, 409
Non-steroidal anti-inflammatory, 173S
Non-steroidal anti-inflammatory drugs, 143S
Noradrenaline, 409, 521

OROS, 204P
Obesity, 551
Ofloxacin, 677
Oral clearance, 317
Oral nitrate, 15
Oral surgery, 437
Oro-caecal transit, 371, 372
Osteoarthritis, 149S, 167S
Ouabain binding, 275
Oxidation, 541
Oxidation phenotype, 194
4-Oxoquinolone, 677
Oxprenolol, 204P

PR interval, 463
Pain, 157S, 167S
Panics, 251
Paracetamol, 111, 217P, 359, 363, 437, 649, 659
Paraxanthine, 177, 183
Parkinson's disease, 429
Paroxetine, 97, 227P
Partial agonist activity, 527
Partial clearance, 317
Patient care, 33S, 41S
Pefloxin, 677
Penbutolol, 469
D-Penicillamine, 244P
Performance, 507
Perindopril, 210P, 233P, 234P
Pharmaceutical industry, 27S, 61S
Pharmacodynamics, 167, 293, 513
Pharmacokinetic–pharmacodynamic model, 1
Pharmacokinetics, 21, 31, 108, 129S, 135S, 143S, 155, 195S, 289S, 297S, 309, 331, 337, 346, 351, 367, 373, 383, 421, 429, 491, 513, 541, 551, 559, 565, 587, 633, 643, 725
Pharmacological tolerance, 27
Pharmacology, 55
Phenobarbitone, 49, 218P, 744
Phenylephrine, 231P
Phenytoin, 241P
Pholcodine, 61
Phosphoinositides, 443
Phospholipids, 213P
Pinacidil, 287

Pindolol, 206P
Pirmenol, 613
Piroxicam, 111S, 117S, 149S, 161S
*Plasmodium falciparum*, 93
Platelets, 118, 201, 443, 623, 685
Polymorphic drug oxidation, 49
Polymorphism, 415, 541, 619, 739
Post-marketing surveillance, 71S, 77S
Potassium, 117
Prazosin, 235P
Pregnancy, 359, 475
Pressure sores, 224P
Professor Crooks, personal tribute, 105S
Profitability, 33S, 41S
Prolactin, 1, 216P
Promethazine, 715
Propranolol, 259S, 267S, 301, 317, 339S, 463, 469, 527
Protein binding, 281, 356, 499, 633
Psoriasis, 455, 627
Psychiatric assessment, 267S
Psychomotor performance, 227P
Psychomotor tests, 81
Psychophysiology, 81
Pyrimethamine, 733
Pyronaridine, 93

Quality of life, 245P
Quinidine, 194, 199, 739
Quinine, 346
Quinolone, 677

REM sleep, 715
Racemic chloroquine, 93
Radionuclide angiography, 319S
Radionuclides, 659
Ranitidine, 346, 663, 749
Raynaud's phenomenon, 449
Reactivity, 487
Rebound insomnia, 143
Record linkage, 77S
Rehabilitation, 161S
Renal function, 339S
Renal impairment, 297S
Residence time, 121
Rheumatoid arthritis, 117S, 167S, 173S, 244P
Rifampicin, 49
Ro15-1788, 421

Salbutamol, 149, 587
Salicylic acid, 135
Saliva concentrations, 613
Sedation, 507, 643
Selectivity, 104
Semisolids, 659
Sex differences, 135, 491
Side effects, 331
Sinus arrhythmias, 691
Skiing, 161S
Sleep, 97, 225P, 715
Slow release, 337
Slow release formulation, 383
Small intestine, 217P
Smoking, 455
Sodium cromoglycate, 373, 389
Sodium salicylate, 43
Sodium valproate, 100
Sorbinil, 241P
Sparteine, 49, 194, 199, 415, 619
Sperm motility, 119
Stereoisomers, 356
Stereoselectivity, 729
Steroids, 627
Surgery, 161S
Sustained release, 571
Sweating, 579
Sympathetic nervous system, 409
Systolic time intervals, 155

Temelastine, 718
Tenoxicam, 111
Tertatolol, 205P
Theobromine, 177, 183
Theophylline, 177, 183, 242P, 337, 351, 383, 571, 603, 617, 669, 677
Therapeutic auditing, 55S
Thiopentone, 224P
Tissue culture, 121S
Toxicity, 736
Training, 61S
Transdermal nitrate, 15
Trazodone, 119, 367
Tremor, 104
Triazolam, 143, 639
Tryptophan, 633
L-Tryptophan, 216P

UK-14,304, 215P

VIP, 149
Valpromide, 269
Vasodilators, 287
Vasopressin, 479
Ventilation, 149
Verapamil, 187, 201, 208P, 273S, 319S, 606
Vitamin $K_1$, 242P, 729

Warfarin, 37, 242P, 729
Working capacity, 339S

Xamoterol, 237P, 595

Yohimbine, 251

ZK 93 426, 228P
Zaltidine, 395
Zero order absorption, 220P